
Research highlights the benefits of natalizumab during pregnancy for women with multiple sclerosis, showing reduced disease activity and improved outcomes.

Research highlights the benefits of natalizumab during pregnancy for women with multiple sclerosis, showing reduced disease activity and improved outcomes.

The ongoing PERSEUS trial explores tolebrutinib's potential as a treatment for primary progressive multiple sclerosis, with results anticipated soon.

Host Jeffrey Wilken, PhD, chats with Marie Namey, APRN, MSCN, about the first day of the 2025 CMSC Annual Meeting in Phoenix, Arizona.

New findings reveal ocrelizumab significantly improves symptoms, cognition, and fatigue in Black and Hispanic patients with relapsing multiple sclerosis.
©2025, Consortium of Multiple Sclerosis Centers and MJH Life Sciences. All rights reserved.